Indoor marijuana grows provide the most control over growing conditions. With a simple setup including a tent, proper lighting, and an air circulation system, home marijuana growers can produce consistent yields. Both soil and hydro systems can be utilized for indoor marijuana grows. Soil setups are generally cheaper and more forgiving, but hydro systems tend to be more common.
Some of the research focuses that were explored in 2018 were: comparison of various agronomic factors on industrial hemp (planting dates, tillage regimens, range of soil fertility, etc.); hemp variety comparison for suitability to PA growing conditions; study of the effectiveness of potential herbicide products; comparison of hemp’s capability for weed suppression to other crops; surveying hemp crops for presence of arthropod and disease pests; evaluation of hemp’s performance for phytoremediation and land reclamation; study of hemp seed oil processing and marketability; development of industrial hemp products (using grain, stalks and flowers); genetic selection for desired hemp variety characteristics; and evaluations of hemp as an animal feed ingredient (cattle).
CBD in any capacity, other than products obtained and approved by a UNMC study or in a drug product approved by the FDA, remain illegal in Nebraska. The Attorney General re-issued a statement today of the law which said "Cannabidiol has been and continues to be included in Nebraska's Uniform Controlled Substances Act's legal definition of 'marijuana'"
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This change applies only to FDA-approved products containing no more than 0.1 percent THC. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
The 113th Congress made significant changes to U.S. policies regarding industrial hemp during the omnibus farm bill debate. The Agricultural Act of 2014 (P.L. 113-79) provided that certain research institutions and state departments of agriculture may grow industrial hemp, as part of an agricultural pilot program, if allowed under state laws where the institution or state department of agriculture is located. The FY2015 appropriations (P.L. 113-235) further blocked federal law enforcement authorities from interfering with state agencies, growers, and agricultural research. (From "Hemp as an agricultural commodity," Congressional Research Service)
There is a general inverse relationship in the resin of Cannabis between the amounts of THC present and the amount of the other principal cannabinoid, CBD. Whereas most drug strains contain primarily THC and little or no CBD, fiber and oilseed strains primarily contain CBD and very little THC. CBD can be converted to THC by acid catalyzed cyclization, and so could serve as a starting material for manufacturing THC. In theory, therefore, low-THC cultivars do not completely solve the problem of drug abuse potential. In practice, however, the illicit drug trade has access to easier methods of synthesizing THC or its analogues than by first extracting CBD from non-drug hemp strains.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.